Bridging the mind and body: exploring venous thromboembolism in psychiatric inpatients.

ObjectiveThis study aimed to identify factors associated with venous thromboembolism (VTE) diagnosis in psychiatric inpatients in Saskatoon, Saskatchewan, Canada.MethodsWe conducted a retrospective case-control chart review of patients admitted to the Dube Centre for Mental Health from January 2007 to December 2021. Cases were individuals aged 18 years and older who received anticoagulation for VTE treatment.

Intranasal racemic ketamine maintenance therapy for patients with treatment-resistant depression: a naturalistic feasibility study.

Background: Ketamine is a promising therapy for treatment-resistant depression due to its rapid onset, although benefits are often transitory, with patients needing maintenance therapy to prevent relapse. Most data supporting ketamine for treatment-resistant depression refers to the intravenous route of administration, leaving alternative routes lacking in data, especially as maintenance regimens. Moreover, the safety of ketamine maintenance therapy is poorly defined.

Intranasal ketamine as a treatment for psychiatric complications of long COVID: A case report.

Background: Neuropsychiatric symptoms associated with long COVID are a growing concern. A proposed pathophysiology is increased inflammatory mediators. There is evidence that typical serotonergic antidepressants have limited efficacy in the presence of inflammation.

Intranasal racemic ketamine for patients hospitalized with treatment-resistant depression: A retrospective analysis.

Most research describing ketamine as a treatment for depression has relied on intravenous dosing. There remains a need for more research to support this treatment with other routes of administration. This was a retrospective chart review of 30 patients hospitalized with unipolar or bipolar treatment-resistant depression who were treated with up to four doses of compounded intranasal racemic ketamine (50 mg or 75 mg).

Opioid toxicity due to CNS depressant polypharmacy: A case report.

The interaction between methadone and central nervous system depressants can cause serious adverse effects, including profound sedation, respiratory depression, coma, and death. This poses a challenge in the treatment of patients with concurrent psychiatric and substance use disorders as the combined use is often unavoidable. We report a case of a patient with opioid use disorder, mood disorder unspecified, chronic pain, and chronic obstructive pulmonary disease who experienced 2 serious episodes of CNS and respiratory depression due to polypharmacy-induced opioid toxicity.

Compounded intranasal racemic ketamine for major depressive disorder: A case report.

Ketamine has been safely used as an anesthetic for over 50 years. More recently sub-anesthetic doses have shown benefit for treatment-resistant depression (TRD). The majority of data on ketamine for depression is based on intravenous administration which is resource intensive and logistically challenging.